Literature DB >> 27387105

The role of 18F-FDG PET/CT in the management of patients with secondary haemophagocytic lymphohistiocytosis.

Y Zheng1, G Hu2, Y Liu2, Y Ma2, Y Dang2, F Li2, H Xing2, T Wang2, L Huo3.   

Abstract

AIM: To investigate the ability of combined 2-[18F]-fluoro-2-deoxy-d-glucose (18F-FDG) positron-emission tomography (PET)/computed tomography (CT) to determine potential causes of secondary haemophagocytic lymphohistiocytosis (sHLH) and to predict prognosis.
MATERIAL AND METHODS: Forty-three patients (male/female 20/23, median age 48.5 years), who were diagnosed with sHLH and underwent FDG-PET/CT before treatment, were retrospectively reviewed. The clinical characteristics were compared to identify the predictors of high-yield FDG-PET/CT. Univariate and multivariate analyses were conducted to identify factors associated with survival. Statistical analysis was performed using SPSS version 19.0.
RESULTS: PET results were helpful in 65.1% (28/43), whilst non-contributory in 34.9% (15/43) of patients with regard to the final diagnosis. Lymphoma was the most common (25/43) reason for sHLH, and patients with focal FDG uptake were more likely to be diagnosed with underlying diseases. C-reactive protein (CRP) was found to be a good indicator for the usefulness of PET/CT in HLH patients. Multivariate analysis showed that therapy regimen (hazard ratio [HR]=4.99, p=0.026), fibrinogen (FBG) <1.5 g/l (HR=3.87, p=0.049) and spleen:mediastinum ratio (SP/M) (HR=7.44, p=0.006) were independent prognostic factors for survival.
CONCLUSION: FDG-PET/CT could be a useful technique for detecting underlying diseases causing sHLH. CRP was a useful predictor of FDG-PET/CT effectiveness. Therapy regimen, FBG level, and SP/M were independent prognostic factors for HLH survival.
Copyright © 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27387105     DOI: 10.1016/j.crad.2016.05.011

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  10 in total

Review 1.  Proliferation through activation: hemophagocytic lymphohistiocytosis in hematologic malignancy.

Authors:  Eric J Vick; Kruti Patel; Philippe Prouet; Mike G Martin
Journal:  Blood Adv       Date:  2017-05-09

2.  F-18 FDG PET/CT in NK/T-Cell Lymphoma that Progressed from Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis.

Authors:  Il-Hyun Kim; Young-Sil An; Su Jin Lee; Joon-Kee Yoon
Journal:  Nucl Med Mol Imaging       Date:  2021-11-17

Review 3.  Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies.

Authors:  Halil Yildiz; Sarah Bailly; Eric Van Den Neste; Jean Cyr Yombi
Journal:  Ther Clin Risk Manag       Date:  2021-04-14       Impact factor: 2.423

4.  Total metabolic lesion volume of lymph nodes measured by 18F-FDG PET/CT: a new predictor of macrophage activation syndrome in adult-onset Still's disease.

Authors:  Liyan Wan; Yuting Gao; Jieyu Gu; Huihui Chi; Zhihong Wang; Qiongyi Hu; Jinchao Jia; Tingting Liu; Biao Li; Jialin Teng; Honglei Liu; Xiaobing Cheng; Junna Ye; Yutong Su; Chengde Yang; Hui Shi; Min Zhang
Journal:  Arthritis Res Ther       Date:  2021-03-30       Impact factor: 5.156

5.  Development and Validation of a Nomogram Based on 18F-FDG PET/CT Radiomics to Predict the Overall Survival in Adult Hemophagocytic Lymphohistiocytosis.

Authors:  Xu Yang; Jun Liu; Xia Lu; Ying Kan; Wei Wang; Shuxin Zhang; Lei Liu; Hui Zhang; Jixia Li; Jigang Yang
Journal:  Front Med (Lausanne)       Date:  2021-12-22

6.  The Role of Pre-therapeutic 18F-FDG PET/CT in Pediatric Hemophagocytic Lymphohistiocytosis With Epstein-Barr Virus Infection.

Authors:  Xia Lu; Ang Wei; Xu Yang; Jun Liu; Siqi Li; Ying Kan; Wei Wang; Tianyou Wang; Rui Zhang; Jigang Yang
Journal:  Front Med (Lausanne)       Date:  2022-01-21

7.  Development and Validation of 18F-FDG PET/CT-Based Multivariable Clinical Prediction Models for the Identification of Malignancy-Associated Hemophagocytic Lymphohistiocytosis.

Authors:  Xu Yang; Xia Lu; Jun Liu; Ying Kan; Wei Wang; Shuxin Zhang; Lei Liu; Jixia Li; Jigang Yang
Journal:  Korean J Radiol       Date:  2022-03-08       Impact factor: 3.500

8.  Differential Diagnosis of Hemophagocytic Syndrome by 18F-FDG PET/CT: A Meta-Analysis.

Authors:  Jun Zhang; Bang He; Jian Wang; Caiyun Ying; Lingfeng Zeng; Shiyi Zheng
Journal:  J Healthc Eng       Date:  2022-01-29       Impact factor: 2.682

9.  18F-FDG PET/CT for Identifying the Potential Primary Diseases and Predicting Prognosis of Secondary Hemophagocytic Lymphohistiocytosis in Children.

Authors:  Ang Wei; Xia Lu; Honghao Ma; Hongyun Lian; Xu Yang; Liping Zhang; Dong Wang; Sitong Chen; Qing Zhang; Zhigang Li; Rui Zhang; Jigang Yang; Tianyou Wang
Journal:  Contrast Media Mol Imaging       Date:  2022-04-16       Impact factor: 3.009

10.  A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis.

Authors:  Samuel A Merrill; Rakhi Naik; Michael B Streiff; Satish Shanbhag; Sophie Lanzkron; Evan M Braunstein; Alison M Moliterno; Robert A Brodsky
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.